Equipped for Discovery


A range of facilities provide expert services and technology to support cancer genomics studies at Memorial Sloan Kettering. The Integrated Genomics Operation (IGO), led by Agnès Viale, is a cutting-edge facility providing genome sequencing and analysis services — from experimental design and sample preparation to data analysis and training.

The Bioinformatics Core Facility, led by Nicholas Socci, assists investigators in analyzing large-scale genomics data. In addition, the facility offers consultation, training, and custom programming, and administers Memorial Sloan Kettering’s high-performance research computing resources.

A comprehensive resource for research involving human tissue, the Pathology Core Facility provides instrumental support to Center investigators conducting genomic investigation of clinical samples. The core staff and pathologists provide a wide range of services — from sample acquisition and banking to tissue-based experimentation, analysis, and data interpretation. The facility is led by Marija Drobnjak and Victor E. Reuter.

The New York Genome Center (NYGC), which launched last year, is a collaboration of 11 New York–based biomedical institutions. Memorial Sloan Kettering is playing a key role in the development of the NYGC, which will be located in lower Manhattan. The NYGC will give scientists at Memorial Sloan Kettering and other institutions enhanced access to high-throughput genome sequencing services as well as computational and bioinformatics support.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.
Terms of Use